Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label study evaluating the safety and tolerability of topical ocular
mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will
be treated for 12 weeks.